Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Smartly-timed sale and share buyback reveal Spectris’ hidden value

Specialist sensor and testing equipment maker Spectris (SXS) surprised the market with the recent announcement (19 Apr) it was selling its Omega Engineering division and returning most of the proceeds to investors via a share buyback.
The shares, which had been languishing close to 12-month lows, jumped 5% to top the FTSE 250 on the day but we believe there is much more to come from this high-quality business.
STATE OF THE ART PRODUCTS
Spectris is one of the world’s leading manufacturers of high-tech instruments, test equipment and software for industrial applications.
Most of its sales come from its ‘platform’ businesses, with a third of generated by its GBK (Hottinger, Bruel & Kjaer) division which provides sensing, testing, modelling and simulation solutions to help customers speed up product development.
GBK’s core products are sensor hardware and data acquisition and analysis software which enable manufacturers to physically and virtually test their products at each stage of development.
Customers mostly come from the automotive, aerospace, industrial and electronics sectors, where products have to rigorously tested and inspected for reliability, durability and high performance under a range of conditions.
Just under a third of group sales come from the Malvern Panalytical division which specialises in the advanced measurement and analysis of materials.
Its technology is used by scientists and engineers to maximise productivity and develop better products by analysing materials right down to the level of particles to get a better understanding of their chemical, physical and structural composition.
Customers include heavy manufacturers, makers of advanced materials, pharmaceutical makers and food producers.
The last of the ‘platform’ businesses is Omega Engineering, which makes sensors for measuring temperature, humidity, flow and pressure and accounts for around 10% of group sales.
Three other divisions make up the rest of its revenue, serving the industrial automation market, life sciences and electronics with products for controlled environments such as laboratories and clean rooms.
ASTUTE CAPITAL MANAGEMENT
The disposal of Omega to US investment firm Arcline for $525 million (£403 million) demonstrates skillful asset management and at the same time how the wider group is being undervalued by the market.
The price represents a multiple of 20.4 times Omega’s adjusted 2021 EBITDA (earnings before interest, taxes, depreciation and amortisation), a considerable premium to Spectris’ own valuation of 11 times last year’s EBITDA according to Shore Capital.
Omega is in good health and will be a ‘highly complementary’ fit with Arcline’s existing controls business Dwyer, but its margins were below those which Spectris considered acceptable.
Faced with the choice of allocating capital to grow the business to a size that was ‘essential to deliver acceptable levels of profitability’, the board decided to offload it to a more suitable owner.
The disposal takes Spectris’ gross sale proceeds to more than £1 billion over the last three years, typically at valuations above the group’s multiple, and leaves it with a much-improved financial profile and a focus on high-precision measurement solutions.
WELL-TIMED BUYBACK
With its strengthened balance sheet, Spectris is now well placed to invest to drive organic growth as well as to invest in R&D (research and development).
It is also eyeing what it calls ‘value-enhancing M&A (merger and acquisition) opportunities, from early-life technologies through bolt-ons to larger-scale acquisitions’ as well as collaborations with third parties which meet its return criteria.
However, given its confidence in the business over the medium term and the low market valuation of the company, the board has decided the best use of its surplus capital right now is actually to buy its own shares.
Therefore, the firm will buy in up to £300 million of its own stock, or nearly 10% of its current market cap, in two tranches of £150 million, the first to be launched shortly and the second dependent on shareholder approval at its AGM on 14 May.
EXPERT VIEWS
Analysts at Shore Capital applauded the sale of Omega given its lower profit margin than the group average, and said the deal ‘highlights the undervaluation of the group’.
With the shares down around 30% year to date and more than that from their high above £40 in September 2021, Shore Capital estimates on a sum-of-the-parts valuation the group trades at a 30% discount to its peers, which implies at least 40% upside from today’s price.
Investment bank Berenberg lowered its current-year earnings estimate to account for the loss of sales from Omega but raised their 2023 and 2024 profit forecasts.
Important information:
These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell.
Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.
Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.
Issue contents
Feature
- Great buying opportunities from the big tech rout
- The companies able to charge more without hurting demand
- Explaining the poison pill defence which could have derailed Musk’s Twitter bid
- How big property funds have performed and the different ways to invest
- Emerging markets: Views from the experts
- The best and worst first quarter performers in emerging markets
- Why Unilever has a 10.5% stake in this small cap drug developer
Great Ideas
- Strong reasons to buy Strix, a global leader in niche market
- Loungers maintains fast growth despite facing consumer headwinds
- Brookfield and Homeserve in talks as broker says shares could be worth £15
- Asia Dragon Trust goes shopping for stocks amid market sell-off
- Smartly-timed sale and share buyback reveal Spectris’ hidden value
- Why B&M remains a great way to beat the squeeze
News
- Novacyt faces £134.6 million NHS legal claim
- Can consumer-facing firms beat the big squeeze?
- Growth stocks continue to struggle as we reveal stocks at 52-week highs and lows
- Shares in mining companies hurt by Chinese lockdowns and operational issues
- Why language services group RWS could be the latest private equity victim